Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dianne S Hirsch

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Expert Review of Anticancer Therapy|February 10, 2007
Cdc42: an effector and regulator of ErbB1 as a strategic target in breast cancer therapyDianne S Hirsch, Wen Jin Wu
Nature Reviews. Cancer|January 17, 2009
Mechanism of E-cadherin lysosomal degradationWen Jin Wu, Dianne S Hirsch
Cellular Signalling|January 8, 2004
Arf GAPs: multifunctional proteins that regulate membrane traffic and actin remodellingPaul A Randazzo, Dianne S Hirsch
Cancer Research|April 6, 2006
Growth and motility inhibition of breast cancer cells by epidermal growth factor receptor degradation is correlated with inactivation of Cdc42Dianne S Hirsch, Yi Shen, Wen Jin Wu
Current Opinion in Cell Biology|August 2, 2003
Arf and its many interactorsZhongzhen Nie, Dianne S Hirsch, Paul A Randazzo
Cancer Research|June 17, 2010
pp60c-Src phosphorylates and activates vacuolar protein sorting 34 to mediate cellular transformationDianne S Hirsch, Yi Shen, Milos Dokmanovic, et al.
Molecular Cancer Therapeutics|June 11, 2009
Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancerMilos Dokmanovic, Dianne S Hirsch, Yi Shen, et al.
The Journal of Biological Chemistry|December 7, 2007
Cdc42 regulates E-cadherin ubiquitination and degradation through an epidermal growth factor receptor to Src-mediated pathwayYi Shen, Dianne S Hirsch, Christy A Sasiela, et al.
Cellular Signalling|July 24, 2012
Small GTPase Rho regulates R-cadherin through Dia1/profilin-1Tabetha M Bonacci, Dianne S Hirsch, Yi Shen, et al.
Molecular Cancer Therapeutics|April 14, 2011
Trastuzumab regulates IGFBP-2 and IGFBP-3 to mediate growth inhibition: implications for the development of predictive biomarkers for trastuzumab resistanceMilos Dokmanovic, Yi Shen, Tabetha M Bonacci, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Expert Review of Anticancer Therapy|February 10, 2007
Cdc42: an effector and regulator of ErbB1 as a strategic target in breast cancer therapyDianne S Hirsch, Wen Jin Wu
Nature Reviews. Cancer|January 17, 2009
Mechanism of E-cadherin lysosomal degradationWen Jin Wu, Dianne S Hirsch
Cellular Signalling|January 8, 2004
Arf GAPs: multifunctional proteins that regulate membrane traffic and actin remodellingPaul A Randazzo, Dianne S Hirsch
Cancer Research|April 6, 2006
Growth and motility inhibition of breast cancer cells by epidermal growth factor receptor degradation is correlated with inactivation of Cdc42Dianne S Hirsch, Yi Shen, Wen Jin Wu
Current Opinion in Cell Biology|August 2, 2003
Arf and its many interactorsZhongzhen Nie, Dianne S Hirsch, Paul A Randazzo
Cancer Research|June 17, 2010
pp60c-Src phosphorylates and activates vacuolar protein sorting 34 to mediate cellular transformationDianne S Hirsch, Yi Shen, Milos Dokmanovic, et al.
Molecular Cancer Therapeutics|June 11, 2009
Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancerMilos Dokmanovic, Dianne S Hirsch, Yi Shen, et al.
The Journal of Biological Chemistry|December 7, 2007
Cdc42 regulates E-cadherin ubiquitination and degradation through an epidermal growth factor receptor to Src-mediated pathwayYi Shen, Dianne S Hirsch, Christy A Sasiela, et al.
Cellular Signalling|July 24, 2012
Small GTPase Rho regulates R-cadherin through Dia1/profilin-1Tabetha M Bonacci, Dianne S Hirsch, Yi Shen, et al.
Molecular Cancer Therapeutics|April 14, 2011
Trastuzumab regulates IGFBP-2 and IGFBP-3 to mediate growth inhibition: implications for the development of predictive biomarkers for trastuzumab resistanceMilos Dokmanovic, Yi Shen, Tabetha M Bonacci, et al.
Pageof 2